香砂养胃丸联合兰索拉唑治疗脾虚气滞型慢性萎缩性胃炎的临床观察  

Clinical Observation of Xiangsha Yangwei Pills Combined with Lansoprazole in the Treatment of Spleen Deficiency and Qi Stagnation Type Chronic Atrophic Gastritis

作　　者：宋敏[1] 陈晓娟 

机构地区：[1]资阳市第一人民医院药剂科,四川资阳610041 [2]资阳市第一医院消化内科,四川资阳610041

出　　处：《中国药房》2017年第36期5095-5097,共3页China Pharmacy

摘　　要：目的:观察香砂养胃丸联合兰索拉唑治疗脾虚气滞型慢性萎缩性胃炎的临床疗效和安全性。方法:120例脾虚气滞型慢性萎缩性胃炎患者随机分为对照组和观察组,每组60例。两组患者均给予常规治疗,在此基础上,对照组患者给予兰索拉唑肠溶片30 mg,qd,早晨空腹服用,观察组患者在对照组治疗基础上加服香砂养胃丸9 g,bid。两组均连续治疗4周。观察并比较两组患者临床疗效、治疗前后中医证候积分和胃镜病理积分,同时记录两组不良反应发生情况。结果:治疗后观察组患者总有效率和显效率分别为95.00%和83.33%,显著高于对照组(86.67%和57.53%),差异均有统计学意义(P<0.05)。治疗前,两组患者中医证候积分和胃镜病理积分比较,差异无统计学意义(P>0.05);治疗后,两组患者中医证候积分和胃镜病理积分显著低于同组治疗前,且观察组显著低于对照组,差异均有统计学意义(P<0.05)。观察组患者不良反应发生率显著低于对照组,差异有统计学意义(P<0.05)。结论:香砂养胃丸联合兰索拉唑治疗脾虚气滞型慢性萎缩性胃炎疗效与安全性均较好,可以显著改善患者临床和病理症状。OBJECTIVE： To observe the clinical efficacy and safety of Xiangsha yangwei pills combined with lansoprazole in the treatment of spleen deficiency and qi stagnation （SSQS） type chronic atrophic gastritis （CAG）. METHODS： A total of 120 patients with SSQS type CAG were randomly divided into control group and observation group, with 60 cases in each group. Both groups received routine treatment. Control group was additionally given Lansoprazole enteric-coated capsule 30 mg, once a day, on an empty stomach in the morning. Observation group was additionally given Xiangsha yangwei pills 59 g, twice a day, on the ba- sis of control group. Both groups were treated for consecutive 4 weeks. Clinical efficacies of 2 groups were observed and com- pared, and TCM syndrome score and pathological integral were observed before and after treatment. The occurrence of ADR was re- corded. RESULTS： After treatment, total response rate and excellent effective rate of observation group were 95.00 % and 83.33 %, which were significantly higher than those of control group （86.67% and 57.53% ）, with statistical significance （P〈0.05）. Before treatment, there was no statistical significance in TCM syndrome score or pathological integral between 2 groups （P〉0.05） ; after treatment, TCM syndrome score and pathological integral of 2 groups were significantly lower than before treatment, and those of observation group were significantly lower than those of control group, with statistical significance （P〈0.05）. The incidence of ADR in observation group was significantly lower than that control group, with statistical significance （P〈0.05）. CONCLU- SIONS： Xiangsha yangwei pill combined with lansoprazole show good therapeutic efficacy and safety for SSQS type CAG and can significantly improve clinical and pathological symptoms.

关 键 词：慢性萎缩性胃炎 脾虚气滞 兰索拉唑 香砂养胃丸 疗效 

分 类 号：R573.3[医药卫生—消化系统]